Suppr超能文献

增加临床试验透明度的法律法规、伦理准则及近期政策。

Legal regulations, ethical guidelines and recent policies to increase transparency of clinical trials.

作者信息

Borysowski Jan, Wnukiewicz-Kozłowska Agata, Górski Andrzej

机构信息

Centre for Studies on Research Integrity, Institute of Law Studies, Polish Academy of Sciences, Warsaw, Poland.

Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland.

出版信息

Br J Clin Pharmacol. 2020 Apr;86(4):679-686. doi: 10.1111/bcp.14223. Epub 2020 Feb 19.

Abstract

Timely and accurate dissemination of outcomes is essential to accomplish main benefits of scientific research including clinical trials. Clinical trial results can be disseminated in two main ways: by publication in a peer-reviewed journal and by posting on a publicly available clinical trial register. The credibility of the literature on clinical trials is significantly diminished because a high percentage of trials is not published. While current legal regulations both in the European Union (EU) and the USA impose a duty to submit summary results of clinical trials to a respective register (EU Clinical Trial Register and ClinicalTrials.gov, respectively), the compliance with this requirement has been generally inadequate. Trial outcomes can be also made accessible by data sharing. However, in spite of the wide promotion of this idea, the access of investigators to participant-level datasets remains limited. The main objective of this review is to discuss current legal regulations, international standards, ethical guidelines and recent policies pertaining to dissemination of clinical trial results.

摘要

及时、准确地传播研究成果对于实现包括临床试验在内的科学研究的主要益处至关重要。临床试验结果可以通过两种主要方式传播:在同行评审期刊上发表以及在公开可用的临床试验注册平台上发布。由于未发表的试验比例很高,关于临床试验的文献可信度显著降低。虽然欧盟(EU)和美国目前的法律法规都规定有义务将临床试验的总结结果提交到各自的注册平台(分别是欧盟临床试验注册平台和美国国立医学图书馆临床试验数据库),但对这一要求的遵守情况总体上并不理想。试验结果也可以通过数据共享来获取。然而,尽管这一理念得到了广泛推广,但研究人员对参与者层面数据集的访问仍然有限。本综述的主要目的是讨论与临床试验结果传播相关的现行法律法规、国际标准、伦理准则和近期政策。

相似文献

1
Legal regulations, ethical guidelines and recent policies to increase transparency of clinical trials.
Br J Clin Pharmacol. 2020 Apr;86(4):679-686. doi: 10.1111/bcp.14223. Epub 2020 Feb 19.
4
Availability of results of clinical trials registered on EU Clinical Trials Register: cross sectional audit study.
BMJ Med. 2024 Jan 12;3(1):e000738. doi: 10.1136/bmjmed-2023-000738. eCollection 2024.
6
Trends and variation in data quality and availability on the European Union Clinical Trials Register: A cross-sectional study.
Clin Trials. 2022 Apr;19(2):172-183. doi: 10.1177/17407745211073483. Epub 2022 Feb 11.
10
Transparency Policies of the European Medicines Agency: Has the Paradigm Shifted?
Med Law Rev. 2017 Aug 1;25(3):456-483. doi: 10.1093/medlaw/fwx002.

引用本文的文献

2
Transparency in the secondary use of health data: assessing the status quo of guidance and best practices.
R Soc Open Sci. 2025 Mar 26;12(3):241364. doi: 10.1098/rsos.241364. eCollection 2025 Mar.
3
Are European clinical trial funders policies on clinical trial registration and reporting improving? A cross-sectional study.
J Clin Transl Sci. 2023 Jul 14;7(1):e166. doi: 10.1017/cts.2023.590. eCollection 2023.
4
Institutional dashboards on clinical trial transparency for University Medical Centers: A case study.
PLoS Med. 2023 Mar 21;20(3):e1004175. doi: 10.1371/journal.pmed.1004175. eCollection 2023 Mar.
5
Affordable Prices Without Threatening the Oncological R&D Pipeline-An Economic Experiment on Transparency in Price Negotiations.
Cancer Res Commun. 2022 Jan 27;2(1):49-57. doi: 10.1158/2767-9764.CRC-21-0031. eCollection 2022 Jan.
7
From publication bias to lost in information: why we need a central public portal for clinical trial data.
BMJ Evid Based Med. 2022 Apr;27(2):74-76. doi: 10.1136/bmjebm-2020-111566. Epub 2020 Dec 10.

本文引用的文献

1
3
Social media and clinical trials: The pros and cons gain context when the patient is at the center.
Cancer. 2018 Dec 15;124(24):4618-4621. doi: 10.1002/cncr.31747. Epub 2018 Oct 19.
5
Publication of lung cancer clinical trials in the Japanese Clinical Trial Registry.
Jpn J Clin Oncol. 2018 Nov 1;48(11):995-1000. doi: 10.1093/jjco/hyy131.
7
Illegitimate authorship and flawed procedures: Fundamental, formal criticisms of the Declaration of Helsinki.
Bioethics. 2019 Mar;33(3):319-325. doi: 10.1111/bioe.12503. Epub 2018 Sep 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验